241 related articles for article (PubMed ID: 27806321)
1. A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.
Ba-Sang DZ; Long ZW; Teng H; Zhao XP; Qiu J; Li MS
Oncotarget; 2016 Dec; 7(51):84468-84479. PubMed ID: 27806321
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.
He YM; Yu C; Li WB; Li ZP; Xu N
J Cell Biochem; 2018 Jan; 119(1):1183-1192. PubMed ID: 28708307
[TBL] [Abstract][Full Text] [Related]
3. Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
Fan Q; Lv W; Xu Y; Dong Y; Xiang Z; Wang J
Curr Pharm Des; 2020; 26(26):3171-3186. PubMed ID: 32067605
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
5. Does the addition of targeted biological agents to first-line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Colorectal Dis; 2014 Sep; 16(9):O300-7. PubMed ID: 24766530
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
[TBL] [Abstract][Full Text] [Related]
7. Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis.
Wu CC; Wang JH; Lin PC; Liang CA; Huang CY; Lien HC; Chen CY; Chou KJ; Su YC
Crit Rev Oncol Hematol; 2020 Jan; 145():102823. PubMed ID: 31783291
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis.
Li Z; Huang Y; Zhao R; Cui Y; Zhou Y; Wu X
Sci Rep; 2018 Jan; 8(1):510. PubMed ID: 29323221
[TBL] [Abstract][Full Text] [Related]
11. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
[TBL] [Abstract][Full Text] [Related]
12. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
[TBL] [Abstract][Full Text] [Related]
13. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Zheng B; Wang X; Wei M; Wang Q; Li J; Bi L; Deng X; Wang Z
BMC Cancer; 2019 Mar; 19(1):280. PubMed ID: 30922269
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
15. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L
Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
17. Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
Wang J; Luo L; Wang D; Guo B; Li J; Yang Z; Tang D
J Cell Biochem; 2018 Feb; 119(2):1521-1537. PubMed ID: 28771807
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
19. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
20. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Giusti RM; Cohen MH; Keegan P; Pazdur R
Oncologist; 2009 Mar; 14(3):284-90. PubMed ID: 19282350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
